ClinicaliQ Trial Snapshot
- Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis — Active Not Recruiting • Phase III • Neurology • NCT01892722.
- Fingolimod was safer and more effective than interferon beta-1a for reducing MS relapses in children.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS) Conditions: Multiple Sclerosis Interventions: Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 240 participants